Celltrion’s biosimilar products for the treatment of autoimmune diseases have successively won bids in major European countries.
According to Celltrion on Jan. 12, Yuflyma (active ingredient: adalimumab) has successfully won a government bid in Italy. Yuflyma was awarded in the adalimumab government bid held in the Italian regions of Friuli-Venezia Giulia (FVG) and Sicily.
With this order, Yuflyma is scheduled to be supplied for four years and six months in the FVG region and for two years in Sicily. Including this achievement, Yuflyma won a total of 12 regional government bids in Italy last year alone.
Yuflyma also won a bid in the Netherlands, where the European Medicines Agency (EMA) is located. It succeeded in the adalimumab bid hosted by ICZON, a pharmaceutical purchasing consortium in the southeastern region of the Netherlands, and is set to be supplied for the next three years.
Another autoimmune disease treatment, Remsima (active ingredient: infliximab), also won a bid for infliximab held in Sicily, Italy, and is expected to be supplied for two years.
Remsima was also awarded in a bid by IZAAZ, a major pharmaceutical purchasing consortium in the Netherlands. IZAAZ is the largest university hospital group in the Netherlands.
Yu Won-sik, the head of Celltrion’s Italian branch, stated, “Yuflyma, a high-concentration formulation, is being increasingly prescribed as it is recognized for its competitiveness as the most similar biosimilar to the original. With the integrated launch of Celltrion, we will be able to establish a differentiated pricing strategy as cost ratio improvements are achieved.”